Golimumab: A Phase 4, UK, Open Label, Single Arm Study on Its Utilization and Impact in Ulcerative Colitis

Trial Profile

Golimumab: A Phase 4, UK, Open Label, Single Arm Study on Its Utilization and Impact in Ulcerative Colitis

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs Golimumab (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Acronyms GO-COLITIS
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 01 Nov 2017 Results (n=140) of the 12-week follow-up of patients in clinical response at week 54, presented at the 25th United European Gastroenterology Week.
    • 01 Nov 2017 Results of the maintenance phase (n=140) presented at the 25th United European Gastroenterology Week
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top